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Abstract.  Endochondral bone formation was induced 
in postnatal rats by implantation  of demineralized rat 
bone matrix.  Corresponding control tissue was gener- 
ated by implanting  inactive extracted bone matrix, 
which did not induce bone formation.  At various 
times, implants  were removed and  sequentially ex- 
tracted with guanidine hydrochloride,  and then EDTA 
and guanidine hydrochloride.  Transforming  growth fac- 
tor 13 (TGF13) in the extracts was quantitated by a  ra- 
dioreceptor assay.  TGF13 was present in demineralized 
bone matrix before implantation,  and the concentration 
had decreased by 1 d after implantation.  Thereafter, 
TGF13 was undetectable by radioreceptor assay until 
day 9.  From day 9-21 the TGF13 was extracted only 
after EDTA demineralization,  indicating tight associa- 
tion with the mineralized matrix.  During this time, the 
content of TGF13 per milligram  soluble protein rose 
steadily and remained high through day 21.  This in- 
creased concentration correlated with the onset of vas- 
cularization and calcification of cartilage.  TGF13 was 
detected only between days 3-9 in the controls;  i.e., 
non-bone-forming implants.  Immunolocalization of 
TGF13 in bone-forming implants  revealed staining  of 
inflammatory cells at early times, followed later by 
staining of chondrocytes in calcifying cartilage and 
staining of osteoblasts. The most intense staining of 
TGFI3 was found in calcified cartilage and mineralized 
bone matrix,  again indicating preferential compart- 
mentalization  of TGF13 in the mineral phase.  In con- 
trast to the delayed expression of TGF13 protein,  north- 
ern blot analysis showed TGF13 mRNA in implants 
throughout the sequence of bone formation.  The time- 
dependent accumulation of TGF13 when cartilage is 
being replaced by bone in this in vivo model of bone 
formation suggests that TGF13 may play a  role in the 
regulation of ossification during endochondral bone 
development. 
T 
RANSFORMING growth factor I~ (TGF13)  t was initially 
characterized  based  on  its  ability  to  transform  the 
phenotype of fibroblasts in vitro (Roberts et al., 1983). 
It is found in normal  tissues  and,  although  it is present in 
highest  concentration  in  platelets  (Assoian  et al.,  1983), 
bone represents  the most abundant  source of the peptide 
(Seyedin  et  al.,  1985, 1986;  Ellingsworth  et  al.,  1986). 
TGF13 exists in two distinct  homodimeric forms,  of which 
TGF[i type 1 predominates  (Cheifetz et al.,  1987) but both 
TGF13 type 1 and TGF13 type 2 have been identified in bone 
(Seyedin  et al.,  1985).  The presence of these peptides in 
bone suggests that they may play a role in bone tbrmation  or 
repair  (Centrella  and  Canalis,  1985;  Robey et al.,  1987; 
Centrella et al., 1987). The fact that TGF[i is present in many 
tissues,  cells, and in serum (O'Connor-McCourt and Wake- 
field,  1987), and that the receptor is also present on a wide 
spectrum of cell types (Wakefield et al., 1987), not only im- 
1. Abbreviations  used in this paper: EDTA-Gdn, EDTA and 4 M guanidine 
extraction buffer; Gdn, 4 M guanidine extraction buffer; TGF13, transform- 
ing growth factor 13. 
plies that it may play a basic role in cellular physiology, but 
also suggests that regulation of its effects is important.  There- 
fore, systems in which TGFI3 may function must be consid- 
ered from the standpoint of regulation  of the bioavailability 
of the factor and regulation  of its activation  from the latent 
form in which it is normally secreted (Miyazono et al., 1988; 
Wakefield et al.,  1988). 
Endochondral  bone develops through a series of events in- 
cluding formation of cartilage, hypertrophy and calcification 
of the cartilage, vascular invasion, appearance of osteoblasts, 
and  formation  of bone.  These events have been studied  in 
embryonic development  (Fell,  1925;  Holder,  1978; Ede, 
1983) and in a postnatal model of bone development (Reddi, 
1981; Reddi,  1984). In both cases the sequence of events is 
remarkably  similar. When  implanted  intramuscularly  or 
subcutaneously  in  rats  (Urist,  1965;  Reddi  and  Huggins, 
1972), demineralized  bone matrix  induces the formation  of 
an ossicle of bone with bone marrow. The cellular processes 
of bone formation induced by implanted demineralized  bone 
matrix  are indistinguishable  from embryonic bone forma- 
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animal. 
The advantages of using this system to study the role of 
TGFI3 in bone development are severalfold. First, the pro- 
cess of matrix-induced bone formation in vivo is well char- 
acterized  and  recapitulates  the  embryonic  developmental 
sequence.  Currently  it  is  impossible  to  investigate  bone 
differentiation in vitro. In addition, while bone formation in 
developing fetal bone or growth plate is a continuum, there 
is only one cycle of bone formation in implants.  Further, 
events take place in a more synchronous fashion throughout 
the tissue such that the predominant phases of bone forma- 
tion  can  be  distinguished  using  biochemical  parameters 
(Reddi,  1981) and can be correlated with biological pro- 
cesses. 
In  the present  study we used the  matrix-induced bone 
forming system to examine the time course of appearance of 
TGFI3 and its localization in developing endochondral bone. 
Proteins are easily extracted from bone by using 4 M guani- 
dine buffers (Gdn) (Sampath and Reddi,  1984;  Seyedin et 
al., 1985; Hauschka et al., 1986), and this extraction proce- 
dure was used to first isolate TGFI3 1 and TGF[~ 2 from ma- 
ture bone (Seyedin et al., 1985). We have used this procedure 
to extract, quantitate, and characterize the TGFI3 in develop- 
ing bone. 
Materials and Methods 
Quantitation of TGF~ Content in Developing 
Endochondral Bone 
New bone formation was induced in 25-30-d-old male Long-Evans rats by 
implanting 30 nag of rat demineralized bone matrix subcutaneously on each 
side of the thoracic region as previously described (Reddi and Huggins, 
1972).  At selected days after implantation, the implants were recovered 
from four rats, yielding eight implants for each time point. One half of two 
implants from different rats at each time point were fixed immediately in 
Bouin's solution for 2 h, then transferred to 70% ethanol until they were em- 
bedded for immunohistochemistry. The remaining implants for each time 
point were pooled, minced, weighed, homogenized, and sequentially ex- 
tracted in guanidine buffer then Gdn plus EDTA buffer (EDTA-Gdn). The 
first extraction was done overnight at 4°C using a filtered solution of 50 mM 
Tris-hydrochloride, pH 7.4, with 4 M guanidine hydrochloride, 100 mM 6- 
aminohexanoic acid, 5 mM benzamidine, 5 mM N-ethylmaleimide, 0.5 mM 
phenylmethylsulfonyl fluoride, and 0.1% CHAPS. After centrifugation for 
15 min at 4°C each supernatant and two washes of the pellet were pooled, 
extensively dialyzed against 0.5 M acetic acid, and lyophylized. The pellets 
were subsequently re,  extracted overnight with Gdn containing 0.5 M EDTA 
to demineralize and further extract the tissues. Extracted proteins from this 
step were processed as described for the first extraction. This two-step ex- 
traction procedure was designed to separate the proteins associated with 
nonmineralized matrix  from  those  associated  with  mineralized  matrix 
(Sampath and Reddi, 1984). Proteins which are strongly associated with the 
mineral component of bone matrix should be extractable only after dissolv- 
ing the mineral with EDTA.  Therefore, the sequentia! extraction with Gdn 
and then with EDTA-Gdn yields bone proteins Which were not associated 
with mineral, then proteins which were bound to the mineral (Sampath and 
Reddi, 1984),  respectively. As a control, nonmineralized tissue which had 
been  similarly  generated  by  implantation  of non-bone-inductive Gdn- 
extracted matrix was extracted according to the same procedure. The previ- 
ously Gdn-extracted demineralized bone matrix residue did not induce new 
bone formation when implanted as for active demineralized bone matrix. 
Instead, it was infiltrated by fibroblast-like cells and slowly resorbed. If 
separation of the mineralized and nonmineralized compartments was effec- 
tive, we expected any TGFI3 present in the nonmineralized control tissue 
to be extracted only in the first extraction. 
To quantitate the amount of  TGFI~ at each time point, an aliquot of  protein 
from each extraction method at each time point was dissolved in 4 mM HCI 
and analyzed in a competitive radioreceptor binding assay.  A549 human 
lung carcinoma cells were plated in DME with 10% FCS. After 24 h, the 
cells were washed twice with 1 ml binding buffer (MEM, 25 mM Hepes, 
0.1% BSA), and competitive binding of TGFI3 to its cellular receptor was 
determined as previously described (Frolik et al., 1984).  Four dilutions of 
each sample were added to ~25I-labeled TGFI3 and the mixture was added 
to each well containing ceils. After incubating at room temperature for 2 h, 
cells were washed four times with Hanks' balanced salt solution with 0.1% 
BSA at 0°C. Cells were solubilized in 1 M Hepes buffer with Triton X-100 
and glycerol for 30 rain at 37°C and triturated thoroughly. Radioactivity in 
aliquots was counted and competitive binding of samples was determined 
after subtracting nonspecific binding (determined in the presence of excess 
unlabeled TGFI3). The quantity of TGFI3 was determined by comparison to 
a  standard dilution curve for TGFI3 (Robey et al.,  1987). 
Analysis ofTGF~ 1 and TGF~-2 Content 
of  Developing Bone 
An assay of TGFI3 inhibition of CCL64 mink lung epithelial cell growth was 
used in combination with specific antibodies to TGF[3 1 and TGFI3 2 to de- 
termine the relative contributions of each form of the protein to the total 
TGFI3 content of developing bone (Rosa et al.,  1988).  CCL64 cells were 
plated in wells of a 24-well plate at a density of 5  x  104 cells per well in 
0.5 ml DME containing 0.2% FBS. After 1 h, bone extracts and antibodies 
were added to the wells as appropriate for the experiment and incubated for 
22 h. At that time 0.5 gCi of 125I-deoxyuridine was added to each well for 
2 h. Cells were fixed, washed, and dissolved in 1 N NaOH, and incorpora- 
tion of ~25I-deoxyuridine was counted as a measure of cell growth. The an- 
tisera used were turkey antiserum to TGFI3 1 and preimmune serum, rabbit 
IgG raised against TGFI3 2 and nonimmune rabbit IgG, and IgG purchased 
from R & D Systems, Inc. (Minneapolis, MN) raised against TGFI~ 1 but 
which has cross-reactivity with TGFI~ 2 (see Results). 
DNA and Protein Determination 
To determine DNA and protein content of each sample, a weighed amount 
of extract was dissolved in TCA and hydrolyzed at 90°C for 20 min, then 
quenched on ice. Samples were centrifuged to remove the insoluble protein 
and the supernatant was used for determination of DNA content using the 
diphenylamine method of Burton (1956).  The protein pellet was dissolved 
in 0.1  N NaOH and heated at 37°C for 30 min. After centrifugation, the 
supernatant was then used for protein determination using a protein assay 
(Bio-Rad Laboratories, Richmond, CA). To determine the total  DNA or 
protein at each time point, the amounts from Gdn extracts and EDTA-Gdn 
extracts were combined at each time point. 
Immunodetection of TGF~ I on Nitrocellulose 
Extracted protein from 12-21-d implants was dissolved in sample buffer and 
210 I.tg of each extract was subjected to eletrophoresis in a  15 % polyacryl- 
amide gel, and then electrophoretically transferred to nitrocellulose. The 
membrane was incubated with turkey antiserum to TGFI~ I in PBS contain- 
ing 0.05%  Tween 20. After washing and incubating with a biotinylated sec- 
ondary antibody, and then peroxidase-conjugated avidin-biotin complex 
(Vector Laboratories, Inc., Burlingame, CA), the membrane was developed 
in 6 mg/ml 4-chloro-l-napthol in a PBS solution containing methanol and 
hydrogen peroxide. 
lmmunolocalization of TG  F~ 
Tissues that had been harvested and fixed as described above were embed- 
ded in paraffin and 5-I.tm sections were made according to standard pro- 
cedures.  After blocking endogenous peroxidase activity,  sections were 
pretreated with  hyaluronidase and  nonspecific binding of antibody  was 
blocked using 0.5% BSA and 1:20 normal goat serum in Tris-buffered sa- 
line. Sections were then incubated overnight with 5 I.tg/ml of either rabbit 
anti-TGFl~  IgG or control IgG in blocking solution.  The antiserum was 
anti-TGFl~  1 IgG prepared by protein A chromatography from rabbit antise- 
rum raised against a peptide corresponding to the first 30 amino acids of 
TGFI3 1 (Heine et al.,  1987).  Control IgG was prepared by preadsorbing 
anti-TGFI3  1 IgG on a TGF~  l-linked affinity column to eliminate TGFI3 
1-specific antibody (Heine et al.,  1987).  Binding of antiserum to sections 
was visualized using biotinylated anti-rabbit secondary antibody (Cappel 
Laboratories, Cochranville, PA) followed by avidin-biotin complex reagent 
(Vector Laboratories, Inc., Burlingame, CA) and development with 0.05 % 
3,  3'-diaminobenzidine. 
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A series of implants was done corresponding to the time points used to quan- 
titate TGFI3. These implants were immediately frozen in liquid nitrogen after 
harvest, then processed for isolation of RNA according to Chirgwin et al. 
(1979). RNA was stored under liquid nitrogen. For northern blot analysis, 
RNA was quantitated using 260 nm OD and equal amounts of whole RNA 
at different time points were taken for electrophoresis. Electrophoresis of 
RNA was done in 1% agarose formaldehyde gels and the gels were stained 
with ethidium bromide and photographed. The RNA was then transferred 
to a gene screen (New England Nuclear, Boston, MA) membrane by capil- 
lary action.  For comparison to RNA from normal tissues, the tibias and 
femurs of 45-d-old rats were dissected clean of adhering tissues and then 
cut into epiphysis and diaphysis. Marrow was cleaned from the bones and 
collected.  RNA was prepared from all three tissues for hybridization to a 
TGFI3  1 probe as were implant tissues as described above. 
RNA was hybridized to an M13 cDNA probe for TGFI~ 1 as previously 
described (Robey et al.,  1987). The probe begins at nucleotide 1,736 and 
ends at nucleotide 1,955  corresponding to amino acids 229-371 of the pre- 
pro TGF~ 1 protein. The cDNA probe was labeled by primer extension with 
32p and hybridized according to the method of Church and Gilbert (1984). 
Blots were washed using 1.5 mM sodium citrate and 15 mM sodium chlo- 
ride with 0.1% SDS at 55°C and exposed to x-ray film for 4-7 d at -70°C. 
To quantitate the hybridization, x-rays were scanned using an ultroscan den- 
sitometer (model 2202;  LKB Instruments, Inc., Gaithersburg, MD). 
Results 
Characterization of  the TGFfl Content of 
Developing Endochondral Bone 
Unlike soft tissues, bone has two major compartments: one 
is composed of cells and unmineralized matrix; the other is 
mineralized matrix. In this experiment the tissues were ex- 
tracted first with Gdn alone to solubilize proteins from the 
unmineralized compartment, and then with EDTA-Gdn to 
demineralize the sample and solubilize proteins which were 
more tightly bound or associated with the mineralized com- 
partment.  The TGFfl which  could be extracted from de- 
veloping bone and control tissues using these procedures was 
quantitated at each time point in a competitive radioreceptor 
binding assay. The results showed that the TGF~ present in 
control, nonmineralized implants, was extracted using Gdn 
alone. TGFI3 was present in 3-9-d Gdn extracts of control 
implants but gave atypical curves in the radioreceptor assay. 
A second assay of these extracts using growth inhibition of 
CCL64 cells showed that TGFI3 was present at 0.5-1.0 ng/mg 
protein. TGFfl was undetectable in the second, EDTA-Gdn 
extracts of control tissues. Just the opposite was true in bone- 
forming implant extracts where TGFI3 was not detected in 
Gdn extracts either by radioreceptor assay or immunoblot- 
ting (see below). Instead, the TGFI3 in developing bone was 
solubilized only after demineralization and was detected in 
the EDTA-Gdn extracts. The radioreceptor assays of EDTA- 
Gdnextracts from bone-forming tissues yielded curves which 
were parallel to the standard curve for TGFfl (Fig. 1 a). The 
concentration of TGFI3 was very low at day 1 and undetect- 
able on days 3-7. Beginning on day 9 of bone formation, the 
concentration of TGFI3 rose steadily through day 14, then re- 
mained high through day 21 (Fig.  1 b). 
TGFI3 was present at 8 ng/mg protein in extracts of adult 
rat bone matrix which had been acid demineralized under 
nondissociative conditions. This was the same matrix that 
was implanted to induce bone formation. As expected, due 
to the prior demineralization, the TGFI3 was extracted from 
this matrix by Gdn alone. This also demonstrated that TGFI3 
was a normal component of adult rat bone matrix. TGFI3 was 
not detected in extracts of demineralized bone matrix which 
had been previously extracted with Gdn (the same matrix im- 
planted to generate control tissues for this assay). 
Day 21 developing bone contained less TGFfl per mg ex- 
tracted protein than the preparation of demineralized bone 
matrix from more mature bone. This suggests that TGFI3 lev- 
els in bone may gradually increase, possibly accompanying 
remodeling processes after day 21.  A  similar  situation is 
found for bone Gla protein, a vitamin K-dependent protein 
containing three residues of y carboxyglutamic acid, which 
also has  an affinity for the mineralized compartment and 
which is continually incorporated into bone matrix that has 
undergone several cycles of remodeling after day 21 (Price 
et al.,  1981; Hauschka and Reddi,  1980). 
To further characterize the TGFI3 in bone-forming tissues, 
immunoblots were done using turkey antiserum to TGFI3 1. 
The results showed that the TGFI3 activity identified by ra- 
dioreceptor assay was also immunologically identifiable as 
TGFI3 1 and was found in EDTA-Gdn extracts but not Gdn 
extracts (Fig. 2). 
Because both q'GFI3 1 and TGFI~ 2 have been found in ma- 
ture bone (Seyedin et al, 1985) we examined the proportion 
of the two types of TGFfl found in 11- and 14-d developing 
bone extracts. Blocking antibodies specific to TGFI3 1 and 
2 were used to neutralize the growth inhibitory activity of 
the extracted TGFI3 on CCL64 cells. Curves generated using 
EDTA-Gdn extracts of bone-forming tissues were parallel to 
the standard curve (Fig. 3 a). In control experiments, either 
TGFI3 1 or TGFI3 2 was added to CCL64 cells in the presence 
of antibodies. As shown in Fig. 3 b, antibody to TGFI3 1 in- 
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Figure 1. Results of assays of 
the ability of EDTA-Gdn ex- 
tracts  to  compete  with  t25I- 
labeled TGFI3 1 for binding to 
A549 cells. (a) TGFI3 1 stan- 
dard curve ([]) and curves for 
binding in the presence of ex- 
tracts from day 11 (¢) and 14 
(a) tissues. (b) Quantities of 
TGFI~ detected at  each time 
point  given as  ng TGFI3/mg 
extracted protein. Data shown 
are the average  of  two separate 
experiments at each time point. 
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hibited TGFI3 1 activity but not TGFI3 2 activity, whereas an- 
tibody to TGFI3 2 inhibited TGFI~ 2 activity but not TGFI~ 
1 activity. In corresponding experiments on  11-d (calcified 
cartilage  stage)  extracts,  62%  of the  TGFI3  activity  was 
blocked by anti-TGFl3 1 antibody and 21% by anti-TGFl~  2 
antibody (Fig. 3 c). In tests of 14-d extracts (bone formation 
stage), 72 % of the TGFI] activity was blocked by anti-TGFI3 
1 antibody and  18%  by anti-TGFl~  2  antibody.  Antibody 
from R & D Systems, Inc., which blocked both TGFI~ 1 and 
2 activity in controls, blocked 90% of the TGFI~ activity in 
extracts at both time points. 
lmmunohistochemistry 
Because  TGFI3  was  present  during  bone  formation  and, 
therefore, could influence bone development, it was impor- 
tant to determine the site of localization. To examine the cel- 
lular and matrix localization of TGBI3 in developing bone, 
sections  of bone-forming  implants  were  stained  using  5 
I.tg/ml anti-TGFl~  1 LC (1-30) IgG or, as controls, with IgG 
previously adsorbed  to  TGFI3;  this  antibody  has  recently 
been shown to stain intracellular sites of synthesis of TGFI3 
(Flanders, K. C., manuscript in preparation). On day 1, the 
cells in the interior of the bone-forming implant were mostly 
granulocytes,  a  subpopulation  of which  contained  TGFI3 
(Fig. 4). TGFI3 was not detected in the cells which formed 
a capsule around the implant or in cells just interior to the 
capsule.  3-d bone-forming implants had very few granulo- 
cytes which were stained for TGFI& By day 7, TGFI~ was de- 
tected in the small amount of calcifying cartilage in the bone- 
forming implants. In 11-d bone-forming implants, the matrix 
of calcified chondrocytes was heavily labeled for TGFI3. In 
addition, staining was  seen in some osteoblasts adjacent to 
forming bone. At day  14 this distribution was  similar with 
staining in osteoblasts, cartilage cells and calcified cartilage 
matrix (Fig. 5). On day 16 and 21, TGFI~ was concentrated 
in newly formed bone matrix, remaining cartilage matrix, 
and osteoblasts. TGFI3 was also detected in granulocytes in 
the forming bone marrow. Interestingly, with LC (1-30) anti- 
body, no TGFI3 was  detected in osteocytes comparable to 
staining seen by Ellingsworth et al.  (1986). Recent experi- 
ments have shown that these antibodies recognize different 
epitopes within the amino-terminal 1-30 amino acid sequence 
of TGFI~ (Flanders, K. C.,  manuscript in preparation). 
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Figure 2. Immunodetection of TGFI~ 1 in extracts of 12-21-d de- 
veloping bone. The first lane contains 10 ng of "I'GFI~ 1. Gu, lanes 
with Gdn extracts at each time point; E, lanes with EDTA-Gdn ex- 
tracts. 
TGF  ~  2  I 
~  "7,  ,  ~  ~  , 
a.  ~  --  .a  a.  --  --  ,~ 
>,  100 
> 
,< 
"5  4o 
.o  20 
..c 
_c 
~  0 
C 
~  0  •  ~  a 
c  ¢  ~  c  c 
Figure  3.  Results of inhibition  of growth  of CC164 cells  by 
EDTA-Gdn extracts in the presence of antibodies to TGFI3 1 and 
2. (a) Standard curve (rq) and ll-d EDTA-Gdn extract curve (,) 
showing growth inhibition of CC164 cells by TGFI3 as measured 
by  incorporation  of  ~25I-deoxyuridine. (b)  Control  experiments 
demonstrating specific inhibition of TGFI3 1 and 2 activity by corre- 
sponding antibodies. (c) Experiments using EDTA-Gdn extracts of 
11-14-d bone-forming implants. Pre, preimmune serum; Anti-l, tur- 
key antiserum to TGF~ 1; Anti-2, rabbit IgG to TGFI~ 2; R & D, 
anti-TGFI3 IgG from R & D Systems, Inc. 
Detection of mRNA for TGF[3 
The TGFI~ detected in developing bone could result from en- 
dogenous production or from adsorption of serum TGFI& 
Since immunohistochemical analysis  indicated TGF~  was 
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polymorphonuclear leukocytes which stain specifically for TGFI3. Bar, 10 vtm. 
present in some cartilage cells and osteoblasts, we examined 
RNA prepared from implants for TGFI3 1 expression. Hy- 
bridization of RNA from developing bone implants with a 
cDNA probe for TGFI3 1 showed that a 2.5-kb transcript was 
present beginning at day 1 and continuing to day 21 with a 
decrease at day 21 (Fig. 6 a). We also examined 45-d-old rat 
epiphysis, diaphysis, and bone marrow for mRNA for TGFI3 
1. mRNA for TGFI3 was present in all three of these normal 
bone tissues including the epiphysis, where the growth plate 
had developmental processes similar to those we examined 
in developing bone implants (Fig. 6 c). 
Discussion 
In vitro studies have indicated that TGF[3 may be important 
in bone development, remodeling, or repair (Robey et al., 
1987;  Pfeilschifter et al.,  1987; Pfeilschifter and Mundy, 
1987).  In the present study, TGF[3 was detected in develop- 
ing endochondral bone in vivo. This is the first evidence that 
TGF[I is present during the process of bone formation, al- 
though it had previously been demonstrated to be in mature 
bone  (Seyedin et  al.,  1985, 1986).  TGF[I  was present in 
highest concentrations at the time when the conversion from 
calcified cartilage to bone was taking place in the implants 
(see Fig. 7),  and consequently when osteoblasts, known to 
both produce and be responsive to TGFI3 in culture, were 
present. 
TGFI3 is found in many cells and tissues and the receptor 
is also widely distributed.  Osteoblasts,  in particular,  have 
high affinity receptors for TGFI3 (Robey et al., 1987). There- 
fore, in order for TGF[3 to have regulatory effects, its activity 
must be precisely controlled within the tissue. The results of 
both extraction and  inlmunohistochemical analysis of de- 
veloping bone indicated that the TGFI3 was tightly bound to 
mineralized matrix  of calcified cartilage  and  bone.  This 
compartmentation of TGFI3 in the mineral phase may be a 
mechanism for storing latent or processed protein. Develop- 
ing bone provides intrinsic possibilities for sequestration and 
accumulation of the protein during bone development and 
perhaps this will be a general biological mechanism for regu- 
lation of factors in bone. In order for the continuing process 
of endochondral bone formation to take place, the calcified 
cartilage matrix with its high concentration of TGFI3, must 
be broken down by chondroclasts. This is a process similar 
to that of  bone remodeling, when existing bone matrix is bro- 
ken down by osteoclasts in a sealed extracellular compart- 
ment which has acidic pH and lysosome-like characteristics 
(Baron et al.,  1985).  Both proteases and acid treatment are 
known to activate TGFI3 from its inactive form (Lawrence et 
al.,  1985;  Miyazono et al.,  1988).  Experiments by Pfeil- 
Figure 5. Sections of 14-d bone-forming implants stained with anti-TGFI3  IgG (a) or control IgG (b). M, implanted matrix particles; large 
arrows, calcified cartilage matrix; small arrows, remaining calcified cartilage cells; arrowheads, osteoblasts. Bar, 10 ~tm. 
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grams  from northern  blots hybridized 
with a C-DNA probe for TGFI3 1.  (a) 
RNA from bone-forming implants at the 
indicated  days after  implantation of 
demineralized bone  matrix.  Bars, the 
levels of 18 and 28 s ribosomal RNA 
bands. (b) Graph of densitometer read- 
ings of the autoradiogram in a. (c) RNA 
from 45-d-old rat diaphysis (D),  bone 
marrow (M), and epiphysis (E). 
schifter and Mundy (1987)  indicate that TGFfl activity in- 
creases in cultures of resorbing calvaria, at least partially due 
to the resorbing of the bone itself. Therefore, the breakdown 
of cartilage matrix during ossification leads to the possibility 
of both release and activation of the TGFI3 in the environ- 
ment provided by osteoclasts and chondroclasts. 
Assuming 1 g tissue is equivalent to 1 ml vol, wet weight 
tissue concentrations of TGFI3 can be estimated from our 
results  to  have been between 2.5  and 49 ng/ml.  The im- 
munohistochemical analysis showed that the TGFI3 was not 
evenly distributed but was concentrated in areas of calcified 
matrix,  indicating  that  local  concentrations of TGFI3 are 
probably much higher than the above estimates. In vitro, os- 
teoblasts and osteoblastic cell lines respond to TGFI3 at con- 
centrations  as  low  as  0.5  ng/ml  by  either  increasing  or 
decreasing proliferation or alkaline phosphatase activity, de- 
pending on the density of the cells and the cell source used 
(Centrella et al.,  1987;  Robey et al.,  1987;  Elford et al., 
1987; Pfeilschifter et al.,  1987). Therefore, if even a small 
portion of the TGFI3 sequestered in the calcified matrix were 
released and active, it could possibly affect surrounding os- 
teoblasts. What effect TGF[3 has on these cells in vivo is not 
clear since, depending on culture conditions and the cells 
used,  various experimenters have reported differing effects 
(Centrella et al.,  1987;  Robey et al.,  1987;  Elford et al., 
1987;  Pfeilschifter et al.,  1987). 
In our experiments, both TGFI3 1 and 2 were present at ap- 
proximately the same proportions at two different times dur- 
ing bone development and these proportions ('~3:1 ratio of 
TGFI3 1 to TGFI] 2) are similar to the proportions of each 
form of the protein reported to be present in mature bone ma- 
trix (Seyedin et al.,  1985).  Since the amount of TGFI3 in- 
creases fourfold between days 11 and 14 (see Fig.  1 b), our 
data suggest that TGFI] 1 and 2 are increased coordinately 
during the process of bone formation. 
Intracellular immunohistochemical localization of TGFI3 
in calcifying cartilage and osteoblasts, and the demonstration 
of mRNA for TGFI] 1 in the forming bone implants suggests 
that the TGFI] extracted from the implants may have resulted 
from local production. The cell types in which TGFI3 could 
be detected immunohistochemically varied with time after 
implantation:  first  inflammatory  cells,  then  cells  in  late 
hypertrophying  and calcifying cartilage, then osteoblasts and 
bone marrow granulocytes stained for TGFI~. However, since 
the increase in TGFI3 content corresponded to the time of 
vascular invasion of the tissue, we can not exclude a contri- 
bution of TGFI3 from serum. 
Northern  blot  analysis  indicated  that  the  increasing 
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Figure 7. Quantities of TGFI~ determined in 
this study in comparison to known parame- 
ters of endochondral bone formation in the 
matrix-induced bone system. Data  for 3~S, 
45Ca,  Alkaline phosphatase,  and  ~gFe are 
from  Reddi (1981). PMN,  polymorphonu- 
clear leukocytes. The increase in TGFI] con- 
tent, as found in the present study, correlates 
with the time of increasing calcium incorpo- 
ration and occurs at the time of appearance 
of calcified cartilage. 
The Journal of Cell Biology,  Volume 107, 1988  1974 amount of TGFI3 in the implants was not due to increased 
transcription. Similar situations are found in both activated 
lymphocytes (Kehrl et al., 1986) and macrophages (Assoian 
et  al.,  1987)  where  TGFI~ mRNA  levels  remain constant 
while  protein  secretion  increases,  suggesting  translational 
rather than transcriptional control. This may be the case in 
the present study as well.  However, because the TGFI3 ap- 
pears to have a high affinity for the mineralized matrix in de- 
veloping bone, the increase in protein content is likely to be 
the result of accumulation of secreted protein after synthesis. 
Both TGFI3  1 and 2  were  present during endochondral 
bone development when the critical transition from calcified 
cartilage to bone was taking place and when osteoblasts, cells 
which can be affected by TGFI3 and which lay down the bone 
matrix during this transition, were present.  We do not yet 
know  what  effects  the  presence  of  TGFI~ may  have  on 
ossification. In addition, whether TGFI3 1 or 2 is more im- 
portant in regulation of bone formation remains to be tested. 
Because of the possible intrinsic regulation of TGFI3 concen- 
tration and  accessibility  in  bone,  its  effects  may  differ  at 
different times. However, the appearance of TGFI3 at the time 
of ossification indicates it may be an important regulator of 
bone development in vivo as well as of cell function in vitro. 
Received  for publication  18  March  1988,  and in  revised  form  1 August 
1988. 
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